TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15523318

Group type: EXPERIMENTAL
Intervention: Simple strategy (stenting the main vessel and balloon dilatation for the side branch)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Complex strategy (stents for both vessels)
Number of subjects: 91
Study: 11517272

Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg orally)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.4 mg, i.v.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9268187

Group type: EXPERIMENTAL
Intervention: Ardeparin sodium (10,000 anti-factor Xa U/ml with different preservatives)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ardeparin sodium (20,000 anti-factor Xa U/ml)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ardeparin sodium (all formulations)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intravenous treatment (control)
Number of subjects: 24
Study: 8302307

Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 52
Study: 3549029

Group type: EXPERIMENTAL
Intervention: Lidocaine (1 mg X kg‐1)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Normal saline (5 ml)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: d‐tubocurarine (0.05 mg X kg‐1)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Diazepam (0.1 mg X kg‐1)
Number of subjects: 160
Study: 30458863

Group type: EXPERIMENTAL
Intervention: Combination gefitinib (250 mg daily for 7 days) and methotrexate (50 mg/m2 single dose)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Methotrexate alone (50 mg/m2 single dose)
Number of subjects: 328
Study: 27028994

Group type: EXPERIMENTAL
Intervention: Using the mathematic model (Group A)
Number of subjects: 103
Study: 26589957

Group type: EXPERIMENTAL
Intervention: Facilitated family case conferencing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study: 23206333

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided core biopsy of small renal masses
Number of subjects: 58
Study: 22007089

Group type: EXPERIMENTAL
Intervention: Online, interactive patient simulation featuring an Arab American Muslim patient (N=97)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group (N=102)
Number of subjects: 199
Study: 18840369

Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg once a day for 6 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rupatadine 10 mg once a day for 6 days with azithromycin 500 mg on day 2 and 250 mg from day 3 to day 6
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rupatadine 10 mg alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rupatadine 10 mg with azithromycin
Number of subjects: 24
Study: 16950473

Group type: EXPERIMENTAL
Intervention: Carotid intima-media thickness (CIMT) measurement and vascular age determination
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: CIMT measurement and vascular age determination
Number of subjects: 506
Study: 12875611

Group type: EXPERIMENTAL
Intervention: Levocarnitine 2g twice daily
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 11203866

Group type: EXPERIMENTAL
Intervention: Tungsten carbide bur in a high‐speed handpiece followed by acid etching
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Air abrasion (27 microns Al2O3) followed by acid etching
Number of subjects: 48

Group type: COMPARATOR
Intervention: Air abrasion (27 microns Al2O3)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Air abrasion (50 microns Al2O3)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: AgNO3 staining (for cavities prepared with bur or air abrasion followed by acid etching)
Number of subjects: 48
Study: 8026000

Group type: EXPERIMENTAL
Intervention: Captopril 12.5 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2657303

Group type: EXPERIMENTAL
Intervention: 2.5 cm H2O PEEP
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 5.0 cm H2O PEEP
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 7.5 cm H2O PEEP
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 10 cm H2O PEEP
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no PEEP)
Number of subjects: 100
Study: 4938245

Group type: EXPERIMENTAL
Intervention: Tetrabenazine 100 mg in divided dosage
Number of subjects: 6

Group type: COMPARATOR
Intervention: Diazepam (control)
Number of subjects: 6
Study: 31530074

Group type: EXPERIMENTAL
Intervention: Combination treatment with radium-223 (Ra-223) and abiraterone acetate plus prednisone or prednisolone (AAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abiraterone acetate plus prednisone or prednisolone (AAP)
Number of subjects: 0
Study: 30460974

Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab
Number of subjects: 160

Group type: COMPARATOR
Intervention: Intravenous abciximab
Number of subjects: 160
Study: 29082651

Group type: EXPERIMENTAL
Intervention: telbivudine (600 mg/d)
Number of subjects: 190

Group type: COMPARATOR
Intervention: entecavir (0.5 mg/d)
Number of subjects: 190
Study: 25098924

Group type: COMPARATOR
Intervention: 8-week proton pump inhibitor (PPI) therapy with 20 mg of omeprazole for 56 days
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 1-week Helicobacter pylori eradication therapy (40 mg of omeprazole, 1,500 mg of amoxicillin, and 800 mg of clarithromycin for 7 days) followed by 7-week rebamipide treatment (300 mg for 49 days)
Number of subjects: 77
Study: 23811317

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training program (12-16Hz-4mm; 3 sessions/week for 12 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training program
Number of subjects: 50
Study: 21067727

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (0.625 mg) with oral medroxyprogesterone acetate (5 mg) on 14 of the 28 days
Number of subjects: 77

Group type: COMPARATOR
Intervention: Natural E(2) gel (1.5 mg) with oral micronized P (200 mg) on 14 of the 28 days
Number of subjects: 77
Study: 19185243

Group type: EXPERIMENTAL
Intervention: Topical lidocaine 8% pH 6.0
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Topical lidocaine 8%
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Topical lidocaine 16% given 6 times
Number of subjects: 36

Group type: COMPARATOR
Intervention: Topical lidocaine 4%, 8%, or 16%
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 17305938

Group type: EXPERIMENTAL
Intervention: Concentric training (CON)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Eccentric training (ECC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 30
Study: 15217654

Group type: EXPERIMENTAL
Intervention: PGE(1)‐induced hypotension
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isoflurane‐induced hypotension
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normotension (Control group)
Number of subjects: 24
Study: 11432535

Group type: EXPERIMENTAL
Intervention: Randomised concentration-controlled trial (RCCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomised effect-controlled trial (RECT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomised biomarker-controlled trial (RBCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomised dose-controlled trial (RDCT)
Number of subjects: 0
Study: 9686663

Group type: EXPERIMENTAL
Intervention: Moderate stage HIE (n = 7)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Severe stage HIE (n = 8)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (healthy term newborns, n = 35)
Number of subjects: 39
Study: 8625167

Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: IL-2 and PEG-IL-2 combination
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: PEG-IL-2
Number of subjects: 124
Study: 2166654

Group type: EXPERIMENTAL
Intervention: 100 micrograms SMS (somatostatin analogue)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Synthetic ACTH (250 micrograms or 63 micrograms)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 7358476

Group type: EXPERIMENTAL
Intervention: Epinephrine hydrochloride (1%)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31452038

Group type: EXPERIMENTAL
Intervention: 6-week mindfulness protocol
Number of subjects: 141

Group type: COMPARATOR
Intervention: 6-week course containing organizational aspects of the medical school
Number of subjects: 141
Study: 30920645

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Standard of care (SoC) chemotherapy
Number of subjects: 326
Study: 28743240

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) with a single dose in the range of 15-24 Gy
Number of subjects: 9

Group type: COMPARATOR
Intervention: Whole brain radiotherapy (WBRT) in five fractions of 4 Gy to a total dose of 20 Gy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 9
Study: 26036936

Group type: EXPERIMENTAL
Intervention: DWI/FLAIR mismatch
Number of subjects: 197

Group type: COMPARATOR
Intervention: PWI/DWI mismatch
Number of subjects: 197
Study: 23432360

Group type: EXPERIMENTAL
Intervention: diet
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: exercise
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: diet + exercise
Number of subjects: 439

Group type: COMPARATOR
Intervention: control
Number of subjects: 439
Study: 22368796

Group type: EXPERIMENTAL
Intervention: Subgingival group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Gingival crest group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Comparison between subgingival and gingival crest groups
Number of subjects: 16
Study: 19412613

Group type: EXPERIMENTAL
Intervention: Standardized pain therapy (Group 2)
Number of subjects: 492

Group type: COMPARATOR
Intervention: Individual and surgery-dependent pain therapy (Group 1)
Number of subjects: 492
Study: 18593536

Group type: EXPERIMENTAL
Intervention: Dermoscopy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Simple observation
Number of subjects: 68
Study: 15161791

Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: Visceral fat
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: Adipocytokines
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: Adiponectin, IL‐6, and PAI‐1
Number of subjects: 1038
Study: 11164762

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 876
Study: 9550533

Group type: EXPERIMENTAL
Intervention: Intense nonpharmacological intervention including a low-fat, high-fiber diet and regular daily physical exercise
Number of subjects: 108
Study: 8064367

Group type: EXPERIMENTAL
Intervention: 210 mumol of vitamin A
Number of subjects: 345

Group type: COMPARATOR
Intervention: 105 mumol of vitamin A
Number of subjects: 345
Study: 3291938

Group type: EXPERIMENTAL
Intervention: Epostane (3-beta hydroxy steroid dehydrogenase inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 30744430

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar fluid (BALF) and plasma biomarkers measured at baseline, day 4 ± 1, and day 8 ± 1.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Historical controls from previous studies (1999 RCT and 2007 biomarker study).
Number of subjects: 90
Study: 28912050

Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme replacement therapy (PERT) for 28 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 90
Study: 24345055

Group type: EXPERIMENTAL
Intervention: Intensive treatment group (n=9) - treated by the same protocol twice a day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Routine care group (n=9) - received physical therapy according to daily custom protocol
Number of subjects: 18
Study: 23149867

Group type: EXPERIMENTAL
Intervention: Group therapy with applied relaxation (n = 33)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Untreated control group (n = 27)
Number of subjects: 60
Study: 22049293

Group type: COMPARATOR
Intervention: Regular bread (control group: n = 39)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Bread with salt content gradually lowered by 52% (reduced group: n = 38)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Bread with salt content gradually lowered by 67% (reduced group: n = 38)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Flavor compensated bread with salt content gradually lowered by 67% (compensated group: n = 39)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Salt reduction in bread (with and without flavor compensation)
Number of subjects: 116
Study: 19001484

Group type: EXPERIMENTAL
Intervention: Extension of the CONSORT checklist for pragmatic trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 16358329

Group type: EXPERIMENTAL
Intervention: Ischemic nerve block applied to the intact hand
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intact foot anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: No anesthesia
Number of subjects: 0
Study: 12637470

Group type: EXPERIMENTAL
Intervention: Troxacitabine plus cytarabine (ara‐C)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Troxacitabine plus topotecan
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Troxacitabine plus idarubicin
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Troxacitabine-based combinations
Number of subjects: 87
Study: 10758468

Group type: EXPERIMENTAL
Intervention: EMLA applied around the base of the affected hallux for at least 1 hour before ring block
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 55
Study: 8925824

Group type: EXPERIMENTAL
Intervention: Gear ratio of 8.87 FR/PCR
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gear ratios of 8.00, 8.87, and 10.06 FR/PCR
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gear ratio maximizing PPO (8.87 FR/PCR)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Increasing gear ratios
Number of subjects: 10
Study: 1372652

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human erythropoietin (r‐HuEPO)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 8
Study: 3901375

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of morphine and bupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epidural saline solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: No epidural catheter
Number of subjects: 0
Study: 31368268

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) applied to unilateral Neixiyan (EX-LE5) and Waixiyan (EX-LE5) for 20 min at 20 Hz
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Soft-tissue relaxing needling (relaxing-needling)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison of relaxing-needling vs. EA
Number of subjects: 40
Study: 30488889

Group type: EXPERIMENTAL
Intervention: 100 mg aspirin
Number of subjects: 15000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15000
Study: 26969417

Group type: EXPERIMENTAL
Intervention: ABT-436 (1,000 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alcohol (0.5 g/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for ABT-436
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for alcohol
Number of subjects: 20
Study: 24527853

Group type: EXPERIMENTAL
Intervention: SRP + PDT (single application of PDT using a 638-nm laser and toluidine blue)
Number of subjects: 22

Group type: COMPARATOR
Intervention: SRP (scaling and root planing alone)
Number of subjects: 22
Study: 22192967

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 500 μg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fluticasone-salmeterol combination, 500/50 μg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Salmeterol, 50 μg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 21129343

Group type: EXPERIMENTAL
Intervention: NovoPen Echo
Number of subjects: 205

Group type: COMPARATOR
Intervention: NovoPen Junior
Number of subjects: 205

Group type: COMPARATOR
Intervention: HumaPen Luxura HD
Number of subjects: 205
Study: 18411915

Group type: EXPERIMENTAL
Intervention: Drotaverine 80 mg
Number of subjects: 345

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 345
Study: 14693963

Group type: EXPERIMENTAL
Intervention: Orlistat (O)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Behavioral intervention combined with placebo (Int+P)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Behavioral intervention combined with orlistat (Int+O)
Number of subjects: 39
Study: 11910714

Group type: EXPERIMENTAL
Intervention: Home visits by nurses providing health and lifestyle advice
Number of subjects: 683
Study: 9653597

Group type: EXPERIMENTAL
Intervention: Potential new agent for diabetic neuropathy (no efficacy demonstrated)
Number of subjects: 1035

Group type: COMPARATOR
Intervention: Standardized foot care education
Number of subjects: 1035

Group type: EXPERIMENTAL
Intervention: Vibration perception threshold (VPT)
Number of subjects: 1035

Group type: EXPERIMENTAL
Intervention: Michigan DPN scores for muscle strength and reflexes
Number of subjects: 1035
Study: 7858504

Group type: EXPERIMENTAL
Intervention: Late intensification chemotherapy
Number of subjects: 192

Group type: COMPARATOR
Intervention: Standard maintenance therapy
Number of subjects: 192
Study: 2918589

Group type: EXPERIMENTAL
Intervention: Intracavernous prostaglandin E1
Number of subjects: 48

Group type: COMPARATOR
Intervention: Phentolamine plus papaverine
Number of subjects: 48
Study: 31904292

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone added to bupivacaine and epinephrine nerve blocks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Bupivacaine and epinephrine nerve blocks without dexamethasone
Number of subjects: 49
Study: 28687482

Group type: EXPERIMENTAL
Intervention: Carboplatin plus nab-paclitaxel with nintedanib (150 mg twice daily)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Carboplatin plus nab-paclitaxel alone
Number of subjects: 170
Study: 26385396

Group type: EXPERIMENTAL
Intervention: RVX-208 200 mg
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study: 24290532

Group type: COMPARATOR
Intervention: Pregabalin (300-600mg/day) in RCT
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: Pregabalin (150-600mg/day) in clinical practice study
Number of subjects: 827
Study: 23712500

Group type: EXPERIMENTAL
Intervention: Overcoming Anorexia Online with clinician guidance (OAO-G)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Overcoming Anorexia Online without clinician guidance (OAO-NoG)
Number of subjects: 37
Study: 21623749

Group type: EXPERIMENTAL
Intervention: Blinded review
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unblinded review
Number of subjects: 40
Study: 19087482

Group type: EXPERIMENTAL
Intervention: Standard pharmacological treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (volunteers)
Number of subjects: 42
Study: 16554515

Group type: EXPERIMENTAL
Intervention: Center-only stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Center-surround stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Center-only and center-surround stimuli
Number of subjects: 0
Study: 12655621

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 11185671

Group type: EXPERIMENTAL
Intervention: Sustained-release (SR) dosage form of clomipramine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Immediate-release (IR) dosage form of clomipramine
Number of subjects: 18
Study: 9264751

Group type: EXPERIMENTAL
Intervention: Hygiene measures, water sanitation, and oral rehydration therapy
Number of subjects: 0
Study: 1532319

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme (ACE) inhibitors
Number of subjects: 2357

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 2357

Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 2357

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 2357

Group type: EXPERIMENTAL
Intervention: Overall antihypertensive therapy
Number of subjects: 2357
Study: 3898450

Group type: EXPERIMENTAL
Intervention: Intraperitoneal 5-fluorouracil (IP 5-FU)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intravenous 5-fluorouracil (IV 5-FU)
Number of subjects: 66
Study: 30521970

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 222

Group type: COMPARATOR
Intervention: Vinorelbine plus cisplatin (VP)
Number of subjects: 222
Study: 29370844

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (AS-AQ Winthrop®)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PPQ, Eurartesim®)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AM-LM, Coartem®)
Number of subjects: 636
Study: 27555604

Group type: EXPERIMENTAL
Intervention: Oral silymarin 420 mg daily in three divided doses for 6 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 24507426

Group type: EXPERIMENTAL
Intervention: CBCT
Number of subjects: 11

Group type: COMPARATOR
Intervention: MDCT
Number of subjects: 11
Study: 21703792

Group type: EXPERIMENTAL
Intervention: Computed Tomography Angiography (CTA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Colour Doppler Ultrasonography (CDUS)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: CTA after balloon angioplasty
Number of subjects: 70

Group type: COMPARATOR
Intervention: CDUS after balloon angioplasty
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: CTA after stent implantation
Number of subjects: 70

Group type: COMPARATOR
Intervention: CDUS after stent implantation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: CTA
Number of subjects: 70

Group type: COMPARATOR
Intervention: CDUS
Number of subjects: 70